The estimated Net Worth of Lawrence G Hamel is at least 178 千$ dollars as of 28 February 2019. Mr Hamel owns over 3,682 units of Acelrx Pharmaceuticals Inc stock worth over 67,126$ and over the last 14 years he sold ACRX stock worth over 111,120$.
Mr has made over 4 trades of the Acelrx Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 3,682 units of ACRX stock worth 10,346$ on 28 February 2019.
The largest trade he's ever made was selling 10,161 units of Acelrx Pharmaceuticals Inc stock on 2 October 2017 worth over 53,752$. On average, Mr trades about 703 units every 14 days since 2011. As of 28 February 2019 he still owns at least 78,053 units of Acelrx Pharmaceuticals Inc stock.
You can see the complete history of Mr Hamel stock trades at the bottom of the page.
Lawrence G. Hamel is the Consultant at Acelrx Pharmaceuticals Inc.
Mr Hamel is 69, he's been the Consultant of Acelrx Pharmaceuticals Inc since . There are no older and 13 younger executives at Acelrx Pharmaceuticals Inc.
Lawrence's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY, CA, 94063.
Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over 25,363,406$ worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth 26,783,172$ . The most active insiders traders include Advisors Llcperceptive Life...、Advisors Llcedelman Josephp...、Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of 109,939$. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth 7,300$.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: